我要投票 老拨云堂在中草药行业中的票数:163
· 外 推 电 报 ·
2025-03-11 05:13:36 星期二

【老拨云堂是哪个国家的品牌?】

老拨云堂是什么牌子?「老拨云堂」是 楚雄老拨云堂药业有限公司 旗下著名品牌。该品牌发源于云南,由创始人殷亦在2005-05-11期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力老拨云堂品牌出海!通过在本页面挂载老拨云堂品牌的产品链接和联系邮箱,可以提高老拨云堂产品曝光!跨境电商爆单神器,目前只要100元/年哦~

老拨云堂始创于雍正六年(1728年),曾与北京同仁堂、天津达仁堂、杭州胡庆余堂并称为中医“四大名堂”,是一家具有300年悠久历史的中华老字号制药企业。

据《云南通志》等史料记载:老拨云堂首开云南制药之先河,公司主导产品--拨云锭,是大理鸡足山得道高僧秘授给老拨云堂始祖的奇方。其选料奇特—-按秘传标准选取药材上品,组方奇特—-动物药+植物药+矿物药,10多味名贵中药材精心炮制,按“五行”精妙配合,堪称一绝。

历史上,老拨云堂曾在昆明开设药店五十余年。拨云锭经“茶马古道”远销全国各地和东南亚。曾成为清皇室贡品,因“宫内眼疾者用之无不见效”而倍受嘉奖,回赠楹联“拨云抽丝眼光若电,云开雾散医道通神”。还一度作为“银锭”流通,民间曾有“身带拨云锭,走遍天下不受穷”之说,堪称眼药中的“奇珍异宝”。老拨云堂也由此成为中国中医眼药当之无愧的代表企业。

为弘扬中医药文明,造福天下眼疾患者,历经10代传承,进入21世纪的老拨云堂进行了一系列的现代化改造,一举通过国家GMP、GSP双项认证,使这个历经百年而不衰的“中华老字号”迈入了现代化医药企业的发展历程,确立了立足中药,依托彝药,把老拨云堂打造成中药眼科第一品牌的发展战略。

英文翻译:Laopiyuntang was founded in 1728. It was once known as the "four famous halls" of traditional Chinese medicine with Beijing Tongrentang, Tianjin Darentang and Hangzhou Huqingyutang. It is a Chinese time-honored pharmaceutical enterprise with a long history of 300 years. According to the historical records such as Yunnan Tongzhi, the company's leading product, Piyun Ding, is the first pharmaceutical pioneer in Yunnan Province. It's a wonderful recipe given to the ancestors of laopiyun hall by the eminent monk in Jizu mountain of Dali. It has a unique selection of materials - top-grade herbs selected according to the secret standard, and a unique composition - animal medicine + plant medicine + mineral medicine. More than 10 precious Chinese herbs are elaborately processed, which can be called a unique combination according to the "five elements". Historically, laopiyuntang has opened a drugstore in Kunming for more than 50 years. Poyun Ding is sold all over the country and Southeast Asia through the ancient tea horse road. It was once a tribute of the Qing Royal family. It was highly praised for "it is effective for those with eye diseases in the palace". In return, it was presented with a couplet "picking the clouds and drawing the eyes like electricity, dispersing the clouds and dispersing the mist to cure the disease and connecting the spirit". It was once circulated as a "silver ingot". There was a saying among the people that "take a cloud ingot with you and walk around the world without suffering poverty". It can be called a "rare treasure" in ophthalmic medicine. Laopiyuntang has become a well deserved representative enterprise of traditional Chinese medicine. In order to carry forward the civilization of traditional Chinese medicine and benefit the patients with eye diseases all over the world, laopiyuntang has carried out a series of modernization transformation after 10 generations of inheritance and entered the 21st century. It has passed the double certification of national GMP and GSP at one stroke, making this century old Chinese brand step into the development process of modern pharmaceutical enterprises, and has established a foothold in traditional Chinese medicine, relying on Yi medicine, to build laopiyuntang into a modern pharmaceutical enterprise Development strategy of the first brand of traditional Chinese medicine ophthalmology.

本文链接: https://www.waitui.com/brand/08f7a91c9.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

我国科学家在抗烧结催化剂研究中取得新进展

36氪获悉,据中国科学技术大学消息,该校曾杰教授团队通过构筑纳米岛结构催化剂,攻克了甲烷干重整反应中催化剂极易烧结失活的难题。相关研究成果3月10日发表于国际学术期刊《自然∙材料》。超细金属纳米颗粒因其超高的原子利用率,在多相催化领域备受青睐。然而,在催化反应过程中,这些纳米颗粒极易受到高温等影响,从而自发聚集并导致活性降低,该过程被称作烧结。发展超细金属纳米颗粒的抗烧结策略,是催化科学领域亟待解决的关键难题。

2小时前

蔚蓝锂芯:2024年净利润4.88亿元,同比增长246.43%

36氪获悉,蔚蓝锂芯公告,公司实现营业总收入67.56亿元,同比增长29.38%;实现净利润5.44亿元,同比增长171.98%;归属于上市公司股东的净利润4.88亿元,同比增长246.43%。公司拟以2024年12月31日总股本1,152,046,537股为基数,向全体股东每10股派发现金红利0.65元(含税)。

2小时前

美股大型科技股盘前全线下跌,特斯拉跌超3%

36氪获悉,美股大型科技股盘前全线下跌,截至发稿,特斯拉、Arm跌超3%,英伟达、亚马逊、谷歌、Meta跌超2%,苹果、微软、奈飞跌超1%。

2小时前

热门中概股美股盘前普跌,B站跌超4%

36氪获悉,热门中概股美股盘前普跌,截至发稿,B站跌超4%,阿里巴巴跌超3%,京东、爱奇艺、腾讯音乐、蔚来、理想汽车、小鹏汽车跌超2%,拼多多、百度跌超1%。

2小时前

新产业:红杉聚业拟减持不超1%公司股份

36氪获悉,新产业公告,公司持股5%以上的股东天津红杉聚业股权投资合伙企业(有限合伙)计划自公告之日起15个交易日后的3个月内通过大宗交易方式减持公司股份不超过总股本的1%。若公司在减持计划实施期间发生送股、资本公积转增股本、配股等变动事项,减持股份数量进行相应调整。减持原因为自身资金需求。

2小时前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询